Q4 2025 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc (FLGT) reported a 14% year-over-year increase in total revenue for 2025, reaching $322.7 million.
- The company successfully launched proprietary imaging management system EOPass, integrating in-house developed AI tools.
- Fulgent Genetics Inc (FLGT) received significant approvals from New York State for its proprietary NIPT offering Nova and whole genome sequencing test, opening new market opportunities.
- The company is advancing its therapeutic development pipeline, with FID-007 progressing to Phase 3 and FID-022 completing Phase 1 dose escalation.
- Fulgent Genetics Inc (FLGT) is making strategic acquisitions, such as Bako Diagnostics and StrataDx, to expand its laboratory services and national client base.
- The company experienced a decrease in Q4 revenue due to lower than anticipated volume from its largest customer transitioning testing in-house.
- Fulgent Genetics Inc (FLGT) anticipates a significant decrease in revenue from its largest customer in the first half of 2026, impacting overall revenue growth.
- Non-GAAP operating margin decreased sequentially to 10.7%, with a GAAP loss of $23.4 million in the current quarter.
- The company expects non-GAAP operating margins to decrease further in 2026 due to incremental expenses from acquisitions and continued investment in R&D.
- Fulgent Genetics Inc (FLGT) is facing a delay in receiving a $106 million federal income tax refund due to a government shutdown in Q4 2025.
Greetings. Welcome to Fulgent Genetics fourth quarter 2025 conference call and webcast. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to Lauren Sloan, Investor Relations.
Thank you. You may begin.
Good morning and welcome to the Fulgent fourth quarter in fiscal year 2025 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer.
The company's press release discussing the financial results is available on the Investor Relations section of the company's website ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website.
Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management estimates based on current
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
